^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Marginal Zone Lymphoma
    Drug:Breyanzi (lisocabtagene maraleucel) (CD19-targeted CAR-T immunotherapy)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Marginal Zone Lymphoma: Suggested treatment regimens…Anti-CD19 CAR T-cell therapy (only after ≥2 prior chemoimmunotherapy regimens…Lisocabtagene maraleucel